Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

2024 ASH Annual Meeting Insights Hub
A

ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin Into Radiation-Free Treatment of Early Stage cHL

By 2024 ASH Annual Meeting Insights Hub FEATURING Ann LaCasce
By 2024 ASH Annual Meeting Insights Hub FEATURING Ann LaCasce
266 views
January 6, 2025
Comments 0
Login to view comments. Click here to Login

Featured Video

14:18
Incyte

Early Intervention in Chronic GVHD: Evaluating Efficacy and Safety O…

Feat. H. Ali

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das
Lymphoma
08:44

ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin I…

2024 ASH Annual Meeting Insights Hub

A. LaCasce

266 views
13:39

ASH 2024 Insights: Acalabrutinib, Venetoclax, and Obinutuzumab in Pa…

2024 ASH Annual Meeting Insights Hub

A. Kim

37 views
12:43

SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?

SOHO 2023 Eleventh Annual Meeting

C. Jacobson

123 views
05:36

Phase 1/2 EPCORE NHL-2 Trial: Investigating Epcoritamab for R/R Foll…

Oncology Data Advisor

R. Merryman

59 views
10:36

ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in High…

Insights from 2023 ASCO® Annual Meeting

R. Merryman

292 views
19:42

Beyond Hyperviscosity: 80 Years and Counting - Treatment of Waldenst…

Indy Hematology Review

S. Treon

36 views
12:50

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldens…

ASH 2022 Conference Coverage

J. Castillo

64 views
13:46

Venetoclax in Previously Treated Waldenström Macroglobulinemia

Dana-Farber Cancer Institute

J. Castillo

26 views